Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID-19 Impact on Neuropathic Pain Market
5.1. COVID-19 Landscape: Neuropathic Pain Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Neuropathic Pain Market, By Drug Class
8.1. Neuropathic Pain Market, by Drug Class, 2025-2033
8.1.1. Anticonvulsant
8.1.1.1. Market Revenue and Forecast (2024-2033)
8.1.2. Tricyclic Antidepressants
8.1.2.1. Market Revenue and Forecast (2024-2033)
8.1.3. Opioids
8.1.3.1. Market Revenue and Forecast (2024-2033)
8.1.4. Capsaicin
8.1.4.1. Market Revenue and Forecast (2024-2033)
8.1.5. Steroids
8.1.5.1. Market Revenue and Forecast (2024-2033)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2024-2033)
Chapter 9. Global Neuropathic Pain Market, By Application
9.1. Neuropathic Pain Market, by Application, 2025-2033
9.1.1. Diabetic Neuropathy
9.1.1.1. Market Revenue and Forecast (2024-2033)
9.1.2. Spinal Stenosis
9.1.2.1. Market Revenue and Forecast (2024-2033)
9.1.3. Chemotherapy-Induced
9.1.3.1. Market Revenue and Forecast (2024-2033)
9.1.4. Peripheral Neuropathy
9.1.4.1. Market Revenue and Forecast (2024-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2024-2033)
Chapter 10. Global Neuropathic Pain Market, By Route of Administration
10.1. Neuropathic Pain Market, by Route of Administration, 2025-2033
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2024-2033)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2024-2033)
Chapter 11. Global Neuropathic Pain Market, By Distribution Channel
11.1. Neuropathic Pain Market, by Distribution Channel, 2025-2033
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2024-2033)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2024-2033)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2024-2033)
Chapter 12. Global Neuropathic Pain Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.1.2. Market Revenue and Forecast, by Application (2024-2033)
12.1.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.1.5.2. Market Revenue and Forecast, by Application (2024-2033)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.1.6.2. Market Revenue and Forecast, by Application (2024-2033)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.2.2. Market Revenue and Forecast, by Application (2024-2033)
12.2.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.2.5.2. Market Revenue and Forecast, by Application (2024-2033)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.2.6.2. Market Revenue and Forecast, by Application (2024-2033)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.2.7.2. Market Revenue and Forecast, by Application (2024-2033)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.2.8.2. Market Revenue and Forecast, by Application (2024-2033)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.3.2. Market Revenue and Forecast, by Application (2024-2033)
12.3.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.3.5.2. Market Revenue and Forecast, by Application (2024-2033)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.3.6.2. Market Revenue and Forecast, by Application (2024-2033)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.3.7.2. Market Revenue and Forecast, by Application (2024-2033)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.3.8.2. Market Revenue and Forecast, by Application (2024-2033)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.4.2. Market Revenue and Forecast, by Application (2024-2033)
12.4.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.4.5.2. Market Revenue and Forecast, by Application (2024-2033)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.4.6.2. Market Revenue and Forecast, by Application (2024-2033)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.4.7.2. Market Revenue and Forecast, by Application (2024-2033)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.4.8.2. Market Revenue and Forecast, by Application (2024-2033)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.5.2. Market Revenue and Forecast, by Application (2024-2033)
12.5.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.5.5.2. Market Revenue and Forecast, by Application (2024-2033)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2024-2033)
12.5.6.2. Market Revenue and Forecast, by Application (2024-2033)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2024-2033)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2024-2033)
Chapter 13. Company Profiles
13.1. Nevro Corp.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Lilly
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Astellas Pharma Inc. (Japan)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Biogen
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Cirtec
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Integer Holdings Corporation
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. B. Braun SE
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Medtronic
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Abbott
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Boston Scientific Corporation
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. OMRON Healthcare Co., Ltd.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
13.12. ElectroCore, Inc.
13.12.1. Company Overview
13.12.2. Product Offerings
13.12.3. Financial Performance
13.12.4. Recent Initiatives
13.13. Polar Medical Ltd
13.13.1. Company Overview
13.13.2. Product Offerings
13.13.3. Financial Performance
13.13.4. Recent Initiatives
13.14. SunMED Medical
13.14.1. Company Overview
13.14.2. Product Offerings
13.14.3. Financial Performance
13.14.4. Recent Initiatives
13.15. NeuroMetrix, Inc.
13.15.1. Company Overview
13.15.2. Product Offerings
13.15.3. Financial Performance
13.15.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
著作権 ©2022 無断複写・転載を禁じます
